{
  "NOTA.F": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS NAM. ADR 1",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NOVN.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "ch_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS N",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NOVNEE.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "ch_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS  N 2. LINIE",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NVS": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Novartis AG",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NVS.BA": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "ar_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS AG",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NVSEF": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS AG",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NVSN.MX": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS AG",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "RHHBF": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HOLDINGS AG",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "RHHBY": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HOLDINGS AG",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "RHHVF": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HOLDINGS AG",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "RHO6.F": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "dr_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HLDG SP.ADR 1/8",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "RO.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "ch_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE I",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "ROG.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "ch_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE GS",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "ROGN.MX": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "mx_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HOLDINGS AG",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  }
}
